PF339 BIOLOGICAL AND CLINICAL FACTORS THAT FAVOR THE USE OF A SPECIFIC TPO-RA IN ITP PATIENTS. RESULTS FROM A SPANISH MULTICENTER STUDY

MLA

Elisa Orna, et al. “Pf339 Biological and Clinical Factors That Favor the Use of a Specific Tpo-Ra in Itp Patients. Results from a Spanish Multicenter Study.” HemaSphere, vol. 3, June 2019, pp. 121–22. EBSCOhost, https://doi.org/10.1097/01.hs9.0000559568.66584.f4.

APA

Elisa Orna, María Perera, María Isabel Orts, Nuria Bermejo, Silvana Novelli, Maria Luisa Lozano, M.T. Álvarez, Felipe Casado, M.F. López, G. Carreño, A. de Andrés, E. López Ansoar, Nuria Revilla, M.E. Mingot, David Valcárcel, Rosa Campos, T.J. González, Isidro Jarque, Estefanía Bolaños, … J.R. González. (2019). Pf339 Biological and Clinical Factors That Favor the Use of a Specific Tpo-Ra in Itp Patients. Results from a Spanish Multicenter Study. HemaSphere, 3, 121–122. https://doi.org/10.1097/01.hs9.0000559568.66584.f4

Chicago

Elisa Orna, María Perera, María Isabel Orts, Nuria Bermejo, Silvana Novelli, Maria Luisa Lozano, M.T. Álvarez, et al. 2019. “Pf339 Biological and Clinical Factors That Favor the Use of a Specific Tpo-Ra in Itp Patients. Results from a Spanish Multicenter Study.” HemaSphere 3 (June): 121–22. doi:10.1097/01.hs9.0000559568.66584.f4.